Interventions for chronic palmoplantar pustulosis.
CONCLUSIONS: Evidence is lacking for major chronic palmoplantar pustulosis treatments such as superpotent corticosteroids, phototherapy, acitretin, methotrexate, and ciclosporin. Risk of bias and imprecision limit our confidence. Maxacalcitol may be more effective than placebo in achieving clearance in the short term (low-quality evidence), and the risk of adverse effects is probably similar (moderate-quality evidence). Oral alitretinoin is probably no more effective than placebo in reducing severity, with a similar risk of adverse effects (moderate-quality evidence). Regarding biological treatments, we are uncertain of the effect of etanercept on clearance and the effect of ustekinumab on severity (low-quality evidence). Secukinumab and guselkumab are probably superior to placebo in reducing severity (moderate-quality evidence). Adverse events not requiring withdrawal were not reported for these treatments. Reporting of serious adverse effects was incomplete: compared to placebo, secukinumab probably caused more participant withdrawals (moderate-quality evidence), but we are uncertain of the effect of guselkumab (low-quality evidence). Future trials should assess commonly used treatments using validated severity and quality of life scales.
PMID: 31958161 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Obeid G, Do G, Kirby L, Hughes C, Sbidian E, Le Cleach L Tags: Cochrane Database Syst Rev Source Type: research
More News: Acitretin | Common Cold | Conjunctivitis | Corticosteroid Therapy | Databases & Libraries | Enbrel | General Medicine | Headache | Methotrexate | Migraine | Psoriasis | Radiation Therapy | Skin | Stelara | Study | Vitamin D | Vitamins